Judah Frommer
Stock Analyst at Morgan Stanley
(3.14)
# 1,072
Out of 4,667 analysts
176
Total ratings
85.71%
Success rate
50.61%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Initiates: Equal-Weight | $31 | $27.52 | +12.67% | 1 | Nov 21, 2024 | |
| RGNX REGENXBIO | Assumes: Overweight | $22 | $9.38 | +134.54% | 1 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $89.25 | +18.77% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $17.78 | +96.91% | 1 | Oct 8, 2024 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $38 | $25.34 | +49.99% | 2 | Apr 22, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $3.38 | +284.62% | 1 | Apr 4, 2024 | |
| PROK ProKidney | Assumes: Equal-Weight | $3 | $1.79 | +67.60% | 1 | Mar 7, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Outperform | $40 | $22.02 | +81.69% | 8 | Aug 14, 2023 | |
| ABOS Acumen Pharmaceuticals | Reiterates: Outperform | $13 | $2.34 | +455.56% | 5 | Aug 9, 2023 | |
| RNA Avidity Biosciences | Reiterates: Outperform | $30 | $43.92 | -31.69% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $11.60 | +98.28% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $43.24 | +15.63% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $111.10 | +26.91% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.72 | +655.81% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $1.55 | +482.52% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $20.27 | +8.56% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $4.28 | +63.55% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $3.08 | +160.16% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $14.34 | +220.78% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.48 | +182.26% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $5.85 | +840.17% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $72.96 | -36.95% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $86.13 | -43.11% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $952.50 | -61.15% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $67.55 | -54.11% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $74.85 | +1.54% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $73.83 | +146.51% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $65.27 | +63.93% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $90.10 | +5.44% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $19.12 | -5.83% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $83.78 | +38.46% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $93.62 | -59.41% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $144.71 | -84.80% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $58.42 | -40.09% | 9 | Apr 29, 2020 |
Apellis Pharmaceuticals
Nov 21, 2024
Initiates: Equal-Weight
Price Target: $31
Current: $27.52
Upside: +12.67%
REGENXBIO
Nov 15, 2024
Assumes: Overweight
Price Target: $22
Current: $9.38
Upside: +134.54%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $89.25
Upside: +18.77%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $17.78
Upside: +96.91%
Galapagos NV
Apr 22, 2024
Maintains: Equal-Weight
Price Target: $38
Current: $25.34
Upside: +49.99%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $3.38
Upside: +284.62%
ProKidney
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $1.79
Upside: +67.60%
Jasper Therapeutics
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $22.02
Upside: +81.69%
Acumen Pharmaceuticals
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $2.34
Upside: +455.56%
Avidity Biosciences
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $43.92
Upside: -31.69%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $11.60
Upside: +98.28%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $43.24
Upside: +15.63%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $111.10
Upside: +26.91%
May 16, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.72
Upside: +655.81%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $1.55
Upside: +482.52%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $20.27
Upside: +8.56%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $4.28
Upside: +63.55%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $3.08
Upside: +160.16%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $14.34
Upside: +220.78%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.48
Upside: +182.26%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $5.85
Upside: +840.17%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $72.96
Upside: -36.95%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $86.13
Upside: -43.11%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $952.50
Upside: -61.15%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $67.55
Upside: -54.11%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $74.85
Upside: +1.54%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $73.83
Upside: +146.51%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $65.27
Upside: +63.93%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $90.10
Upside: +5.44%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $19.12
Upside: -5.83%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $83.78
Upside: +38.46%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $93.62
Upside: -59.41%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $144.71
Upside: -84.80%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $58.42
Upside: -40.09%